1. Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study .
- Author
-
Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, Pereira J, Mayer J, Hong X, Okamoto R, Pei L, Rooney B, van de Velde H, and Cavalli F
- Subjects
- Adult, Aged, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Lymphoma, Mantle-Cell mortality, Male, Middle Aged, Progression-Free Survival, Survival Analysis, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Bortezomib administration & dosage, Lymphoma, Mantle-Cell drug therapy
- Abstract
The pivotal LYM-3002 study compared frontline rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with bortezomib, rituximab, cyclophosphamide, doxorubicin and prednisone (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients for whom stem cell transplantation was not an option. This post hoc subanalysis of the VR-CAP data from LYM-3002 evaluated the effect of bortezomib dose intensity on OS in patients who completed ≥6 cycles of treatment. From the end of cycle 6, patients receiving ≥4.6 mg/m
2 /cycle of bortezomib had significantly longer OS (but not PFS) compared with those receiving <4.6 mg/m2 /cycle by univariate analysis (HR 0.43 [95% CI: 0.23-0.80]; p = .0059). This association remained significant in multivariate analysis adjusting for baseline patient and disease characteristics (HR 0.40 [95% CI: 0.20-0.79]; p = .008]. Higher bortezomib dose intensity was the strongest predictor of OS in newly diagnosed MCL patients receiving VR-CAP. Clinicaltrials.gov identifier: NCT00722137.- Published
- 2019
- Full Text
- View/download PDF